Organon & Co. (NYSE:OGN) Receives $20.80 Average Target Price from Brokerages

Organon & Co. (NYSE:OGN) has earned an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $20.80.

Several research firms recently commented on OGN. Morgan Stanley reduced their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th.

Organon & Co. Price Performance

NYSE OGN opened at $15.63 on Tuesday. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The stock has a 50-day moving average of $15.46 and a 200 day moving average of $16.60. The company has a market capitalization of $4.03 billion, a price-to-earnings ratio of 4.69, a PEG ratio of 0.90 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. On average, sell-side analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.17%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

Hedge Funds Weigh In On Organon & Co.

Several large investors have recently modified their holdings of the stock. Prospera Private Wealth LLC bought a new position in Organon & Co. in the 3rd quarter valued at $25,000. Horizon Bancorp Inc. IN grew its position in Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares during the last quarter. Millstone Evans Group LLC bought a new position in Organon & Co. in the 4th quarter valued at $29,000. Larson Financial Group LLC grew its position in Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after acquiring an additional 1,734 shares during the last quarter. Finally, Riverview Trust Co grew its position in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after acquiring an additional 1,292 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.